JUL 0 3 2003

Sheet

PTO/SB/08a (05-03) Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Compl te if Known

Application Number 10/051.776

Filing Date 01/16/2002

First Named Inventor Edward Pierson

Art Unit 1614

Examiner Name

Attorney Docket Number 100507-1

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (If known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant - Figures Appear
(40)		<sup>US-</sup> 5914401 A	06/22/1999	Egle et al.	:
2		<sup>US-</sup> 6552054 B1	4/22/2003	Yasuma et al.	
		US-		·	· / _ =
		US-			\$∧
		US-			, C
		US-			EC, 41
		US-			Coon
		US-	·		1/2 20 1
		US-			(A) (B)
		US-			600
		Us-			300
		US	•	. 1	0
		US-		:	
		US-			
		US-			
		US-	<del></del>		
		US-	· ·		1. 1
		US-			

			FOREIG	N PATENT DOCL	MENTS		
Exeminer Initials*	Cite No.1		Patent Document  Ide <sup>3</sup> -Number <sup>4-</sup> Kind Code <sup>6</sup> (If <i>known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ6
Sch		EP	0104018 A2	03/28/1984	Fisons PLC.		
S		EP	0017578	10/15/1980	C M Industries Societe Anonyme Dite		1-
0		DE	2331138 A	01/10/1974	Fujisawa Pharmaceutical Co. Ltd.		=
							-
			1		<del></del>		

Examiner Signature

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant, 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Paterit Documents at <a href="https://www.usplo.gov">www.usplo.gov</a> or MPEP 901.04. The Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3) Folia or with Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check main the document under WIPO Standard ST. 16 if possible. Described the serial resolution is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which, is to-fid, (and-by-the, and USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 frours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case: "Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent... and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND T: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JUL 0 3 2003



PTO/SB/06b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT-OF COMMERCE suction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

	C mpl t if Kn wn	(C)
Application Number	10/051,776	15 1
Filing Date	01/16/2002	Con o
First Named Inventor	Edward Pierson	(C) 200
Art Unit	1614	1/2
Examiner Name		02
Attorney Docket Number	100507-1	- Un

		NON PATENT LITERATURE DOCUMENTS	1 :
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city	
Sys	/	FRANK KERRIGAN ET AL, "Synthesis of Arylpiperazines via Palladium-Catalysed Aromatic Amination Reactions of Bromoarenes with N-tert-butoxycarbonylpiperazine," Tetrahedron Letters, Volume 39, 1998, p. 2219-2222,	
53	. /	Internation   Search Report	
:			
. :	. :	•	237
	·	La L	-1087 () is
	÷	er transfer	Terminater part
Examiner:	(	Jahr Cake 1/3x/64	_ 

•	<u> </u>
*EYAMINED: Initial if mfamore accelded to the the second state of	
"EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line	through citation if not in conformance and not
considered. Include copy of this form with next communication to applicant.	
CONSIDER OF THE GOOD SUPPLY OF THIS TOTAL MICH HEXT CONTINUESTION TO BODICEUE	1 - 1

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete including gathering; preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case, any comments on the amount of time you require to complete this form and/or suggestions, for reducing this burden should be sent to the Chief Information Officer U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

in conformance and not considered. PTO/SB/Q8 (2-92)



Sheet 1 of 1

DOCKET NUMBER US APPLICATION NUMBER Form PTO-1449 100507 - 1 10/051,776 APPLICANT · INFORMATION DISCLOSURE CATAGON AstraZeneca AB BY APPLICANT GROUP ART UNIT FILING DATE Not Known January 16, 2002 (Use several sheets if necessar TO BURNETENT DOCUMENTS Examiner Class Subclass Filing Date ... Document Date Name Initial Number If Appropriate 3,862,143 January 21, 1975 Klutchko et al. February 10, 1976 3,937,837 Klutchko et al. 4,189,498 February 19, 1980 Kabbe et al. 4,307,020 December 22, 1981 Kabbe et al. Kurono et all 5,171,865 December 15, 1992 FOREIGN PATENT DOCUMENTS **Document Number** Public Date Country Class Subclass <u>Translation</u> WO 9734883 September 25, 1997 PCT EP 0000377 January 24, 1979 XX ·· **EPO** WO 9827058 June 25, 1998 PCT WO 9827080 June 25, 1998 PCT WO 9914207 March 25, 1999 PCT WO 9914212 March 25, 1999 PCT WO 9914213 March 25, 1999 PCT WO 0012623 / March 9, 2000 PCT March 8, 2001 WO 01/161127 PCT JP 2001-261657 Sept 26, 2001 JP . The relevant sections have been translated OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Chemistry Letters 1997, Raposo et al. "The Effect of Chromenone Receptors on the Selectivity of the Reaction between Pyrrolidine and 5-Hydroxymethyl-2-(5H)-Furanone", pp 173-174. Journal of Medicinal Chemistry, Clitherow et al, "Evolution of a Novel Series of . . . . Antagonists", Volume 37, No 15, pp 2253-2257 \_::\_.. DATE CONSIDERED **EXAMINER** EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP \$609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. PTO/SB/08 (2-92) Patent and Trademark Office, U.S. Department of Commerce

/	0	1	1	D.E.	\
•	JUN	2	5	2002	<b>JC58</b>

Form PTO-1449 2nd INFORMATION BY APPLICANT

FILING DATE

Sheet 1 of 1 US APPLICATION NUMBER ... 10/051,776

DOCKET NUMBER 100507 - 1 APPLICANT AstraZeneca AB

January 16, 2002

GROUP ART UNIT Not Known

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
O	5,403,842	April 4, 1995	Leonardi et al.			
Sh	5,605,896	February 25, 1997	Leonardi et al.			<u> </u>
	·5,965,575	October 12, 1999	Peglion et al.			
200	5,968,954	October 19, 1999	Peglion et al.		<u> </u>	<del>-</del>
				•	!	!

FOREIGN PATENT DOCUMENTS

	Document Number	Public Date	Country	Class	Subclass	Trans	lation
6		·			:	Yes	No
8%	WO 99/05140 /	February 4, 1999	PCT				
X	WO 00/40554	July 13, 2000	РСТ				)
930	WO 01/16127	March 8, 2001	PCT			XX,	
1	:						
•	1					-	
				. ;			
÷				·			
i	i i						
:						1	

This reference is being resubmitted in its entirety because when it was submitted in the original IDS dated April 15, 2002 part of a page was missing.

	OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages, L	tc.)	÷ ,	i nyadiatnicy. V
(0)	International Search Report	•	•		11 0111117 11101
			:		
			:		
				大グ	7, maccol, cress, 7, cob 24,
	. /			<u>. 871</u>	/ Halazy, et et.,
EXAMINE (1)	a film by file	DATE CONSIDERED 1 3 GL	1	(g.57)	Geven et al., ' Antidepressari E
EXAMINE	R: Initial if citation considered, whether or not citation		Draw	line thro	ugh citation if not

in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08 (2-92)

Patent and Trademark Office, U.S. Department of Commerce, a considered.

its conformance and not appricate to the

FTO/SB/08 (2-92)

4-Tax sadistayor รัษฐอยกระ", ∤ ::-

/	OIF	E	7
	AUG 2	2 2002	PCE 9
13	<b>S</b>		87

Sheet 1 of 1

## INFORMATION DISELOSURE CITATION BY APPLICANT

(Use several sheets if necessary)

Form PTO-1449

DOCKET NUMBER 100507 - 1	US APPLICATION NUMBER 10/051,776		
APPLICANT AstraZeneca AB	, ·		
FILING DATE January 16, 2002	GROUP ART UNIT		

Examiner Initial	Document Number	Date _	Name	Class	Subclass	Filing Date If Appropriate

Čkasa. <u>Translation</u> Yes No Document Number **Public Date** Subclass Country

, •
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
Gaster, et al., "The Selective 5-HT <sub>1B</sub> Receptor Inverse Agonist 1'-Methyl-5-[[2'-methyl-4'-(5-methyl-1,2,4-
\(\sigma_A \)   oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289)
Potently Blocks Terminal 5-HT Autoreceptor Function Both in Vitro and in Vivo" J. Med. Chem., 41, 1218-
2 / 1235 (1998)
Russell, et al., "3-[3-(Piperidin-1-yl)propyl]indoles as Highly Selective h5-HT <sub>1D</sub> Receptor Agonists", J. Med.
Chem., 42, 4981-5001, (1999)
Barnes, et al., "A review of central 5-HT receptors and their function", Neuropharmacology 38, 1083-1152,
/ (1999)
Massot, et al., "5-HT1B Receptors: A Novel Target for Lithium", Neuropsychopharmacology Vol. 21, No. 4,
<u>9</u> / 530-541
Halazy, et al., "5-HT <sub>18/1D</sub> antagonists and depression", Exp. Opin. Ther. Patents, 7(4) 339352 (1997)
Cryan et al., "5-HT <sub>1A</sub> and Beyond: The Role of Serotonin and its Receptors in Depression and the
Antidepressant Response", Hum. Psychopharmacol. Clin. Exp., 15, 113-135 (2000)
EXAMINER
1 (1/26)
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if no
I in conformance and not considered : Include conv of this form with next communication to applicant

PTO/SB/08 (2-92)

Patent and Trademark Office, U.S. Department of Commerce